Clinical outcomes in patients with COVID-19 and gynecologic cancer: A society of gynecologic oncology COVID-19 and gynecologic cancer registry study.

Autor: Glaser GE; Mayo Clinic Division of Gynecologic Surgery, Department of Obstetrics and Gynecology, United States of America. Electronic address: glaser.gretchen@mayo.edu., Lara OD; Department of Obstetrics and Gynecology, NYU Langone Health, Perlmutter Cancer Center, New York, NY, United States of America., Pothuri B; Department of Obstetrics and Gynecology, NYU Langone Health, Perlmutter Cancer Center, New York, NY, United States of America., Grimaldi CG; Vanderbilt, United States of America., Prescott LS; Vanderbilt, United States of America., Mastroyannis SA; University of Pennsylvania, United States of America., Kim S; University of Pennsylvania, United States of America., ElNaggar AC; West Cancer Center and Research Institute, Memphis, TN, United States of America., Torres D; Oschner Health, United States of America., Conrad LB; Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Creighton University School of Medicine, Omaha, NE, United States of America., McGree M; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States of America., Weaver A; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States of America., Huh WK; Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Alabama at Birmingham Heersink School of Medicine, United States of America., Cohn DE; Ohio State University, James Cancer Hospital and Solove Research Institute, United States of America., Yamada SD; Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicago Medicine, United States of America., Fader AN; Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, United States of America.
Jazyk: angličtina
Zdroj: Gynecologic oncology [Gynecol Oncol] 2022 Nov; Vol. 167 (2), pp. 146-151. Date of Electronic Publication: 2022 Sep 23.
DOI: 10.1016/j.ygyno.2022.09.017
Abstrakt: Objectives: Patients with gynecologic malignancies may have varied responses to COVID-19 infection. We aimed to describe clinical courses, treatment changes, and short-term clinical outcomes for gynecologic oncology patients with concurrent COVID-19 in the United States.
Methods: The Society of Gynecologic Oncology COVID-19 and Gynecologic Cancer Registry was created to capture clinical courses of gynecologic oncology patients with COVID-19. Logistic regression models were employed to evaluate factors for an association with hospitalization and death, respectively, within 30 days of COVID-19 diagnosis.
Results: Data were available for 348 patients across 7 institutions. At COVID-19 diagnosis, 125 patients (36%) had active malignancy. Delay (n = 88) or discontinuation (n = 10) of treatment due to COVID-19 infection occurred in 28% with those on chemotherapy (53/88) or recently receiving surgery (32/88) most frequently delayed. In addition to age, performance status, diabetes, and specific COVID symptoms, both non-White race (adjusted odds ratio (aOR) = 3.93, 95% CI 2.06-7.50) and active malignancy (aOR = 2.34, 95% CI 1.30-4.20) were associated with an increased odds of hospitalization. Eight percent of hospitalized patients (8/101) died of COVID-19 complications and 5% (17/348) of the entire cohort died within 30 days after diagnosis.
Conclusions: Gynecologic oncology patients diagnosed with COVID-19 are at risk for hospitalization, delay of anti-cancer treatments, and death. One in 20 gynecologic oncology patients with COVID-19 died within 30 days after diagnosis. Racial disparities exist in patient hospitalizations for COVID-19, a surrogate of disease severity. Additional studies are needed to determine long-term outcomes and the impact of race.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: